BioOutsource Opens New Facility in Glasgow
Double’s the Company’s Capacity for Biologics Contract Testing and Biosimilar Characterisation
BioOutsource Ltd., part of Sartorius Stedim Biotech Group, announced the opening of a new facility which doubles Biooutsource’s capacity for future growth.
“Our opening of this new, state-of-the-art facility demonstrates our commitment to our growing list of global customers,” commented BioOutsource CEO, Gerry MacKay. “Demand for our services remains high and we are doubling our capacity to make sure we are ready to support the robust pipeline of biotech and biosimilar products currently in development. It is estimated that in opening and running the new facility, BioOutsource will create approximately 50 new jobs for scientific and technical professionals in the next six months."
Mr. MacKay continued, “This is a great opportunity for Life Science professionals to join an exciting and rapidly growing company. With the recent acquisition by Sartorius Stedim Biotech we expect to become one of the largest employers in this sector in Scotland and further investment in new services is already planned”.
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
The Gene Center at Ludwig-Maximilians-Universität München and ExpreS2ion Biotechnologies Enter a Licensing Agreement

The 2024 Balzan Prizes Focus on Sustainable Progress - From Law to the History of Science, and from the Biology of Ageing to Innovative Materials: 750,000 Swiss Francs will be awarded to each of the four winners of the Balzan Prizes
Clavis Pharma expands Phase III CLAVELA study in patients with acute myeloid leukaemia (AML)
50-year search for calcium channel ends

BASF to invest USD 33 million in R&D facilities in Research Triangle Park - Focus on plant biotechnology and crop protection research
Shock_(medical)

108Labs is building the world’s first cell cultured human milk factory
Recommendations to expand access to clinical trial data
